ContraFect
OverviewSuggest Edit
ContraFect is a clinical stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. The Company's most advanced product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia and CF-404, a cocktail of monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza.
| Type | Public | |
| Founded | 2008 | |
| HQ | Yonkers, US | Map |
| Website | contrafect.com | |
| Employee Ratings | More |
Recent NewsAll News
- ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation
- ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
- ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
- Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
Key People/Management at ContraFect
Roger J. Pomerantz
President, Chief Executive Officer and Chairman of the Board
David N. Low
Director
Michael J. Otto
Director
Cary W. Sucoff
Director
Cara Cassino
Chief Medical Officer and Executive Vice President of Research and Development
Sol Barer
Lead Director
ContraFect Office Locations
ContraFect has an office in Yonkers
Yonkers, US (HQ)
28 Wells Ave
ContraFect Financials and Metrics
ContraFect Revenue
| USD | |
|---|---|
Net income (Q2, 2020) | (17.6m) |
EBIT (Q2, 2020) | (8.2m) |
Market capitalization (15-Oct-2020) | 148.5m |
Closing stock price (15-Oct-2020) | 5.3 |
Cash (30-Jun-2020) | 30.8m |
EV | 121.4m |
ContraFect's current market capitalization is $148.5 m.
Annual
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.2m | 2.3m | 2.3m | 2.9m | 2.4m | 4.7m | 2.5m | 1.9m | 2.1m | 2.3m | 1.8m | 2.2m | 2.1m | 2.3m | 2.6m | 2.4m | 3.0m | 2.6m |
R&D expense | 1.5m | 2.4m | 2.4m | 4.3m | 3.4m | 4.4m | 7.3m | 5.9m | 4.2m | 3.8m | 4.9m | 5.3m | 5.7m | 4.1m | 4.8m | 5.3m | 5.1m | 5.5m |
Operating expense total | 2.7m | 4.6m | 4.7m | 7.2m | 5.7m | 9.2m | 9.8m | 7.9m | 6.3m | 6.1m | 6.7m | 7.5m | 7.8m | 6.4m | 7.4m | 7.6m | 8.1m | 8.2m |
EBIT | (2.7m) | (4.6m) | (4.7m) | (7.2m) | (5.7m) | (9.2m) | (9.8m) | (7.9m) | (6.3m) | (6.1m) | (6.7m) | (7.5m) | (7.8m) | (6.4m) | (7.4m) | (7.6m) | (8.1m) | (8.2m) |
Annual
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 2.2m | 31.3m | 12.4m | 23.6m | 20.8m | 7.6m | 10.6m | 10.7m | 4.7m | 4.9m | 4.3m | 4.6m | 11.0m | 6.8m | 7.4m | 10.5m | 10.6m | 30.8m |
Prepaid Expenses | 248.3k | 417.1k | 271.7k | 1.1m | 946.0k | 1.1m | 1.5m | 1.1m | 1.5m | 2.2m | 1.3m | 2.2m | 1.8m | 2.1m | 2.0m | 2.3m | 5.6m | 5.3m |
Current Assets | 2.4m | 31.7m | 23.2m | 36.3m | 30.4m | 27.4m | 20.6m | 44.4m | 30.3m | 23.9m | 53.8m | 35.5m | 39.4m | 25.1m | 16.2m | 12.8m | 22.3m | 45.0m |
PP&E | 2.5m | 2.3m | 2.0m | 1.9m | 1.7m | 1.5m | 1.5m | 1.3m | 1.2m | 1.2m | 1.1m | 1.1m | 1.1m | 1.2m | 1.2m | 1.1m | 1.1m | 1.0m |
Annual
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (9.0m) | (25.4m) | (4.9m) | (12.0m) | (17.5m) | (8.9m) | (18.6m) | (29.1m) | (6.3m) | (9.2m) | (10.8m) | (39.2m) | (43.6m) | 11.6m | 2.9m | (2.4m) | (7.6m) | (25.2m) |
Depreciation and Amortization | 279.3k | 414.7k | 134.3k | 268.7k | 403.0k | 134.4k | 268.9k | 385.0k | 45.6k | 91.1k | 133.0k | 71.1k | 110.3k | 42.0k | 84.4k | 126.8k | 42.4k | 84.7k |
Accounts Payable | 490.0k | (1.6m) | (491.4k) | 559.7k | (420.2k) | 1.2m | 3.5m | 2.7m | 8.7k | (787.3k) | (1.5m) | 52.6k | 770.7k | (453.1k) | (2.5m) | 1.3m | (1.2m) | (4.2m) |
Cash From Operating Activities | (4.9m) | (11.0m) | (4.5m) | (10.4m) | (16.3m) | (6.5m) | (13.5m) | (21.3m) | (6.2m) | (13.2m) | (19.2m) | (13.2m) | (19.2m) | (7.3m) | (16.1m) | (19.8m) | (7.5m) | (17.7m) |
| USD | Q2, 2014 |
|---|---|
Debt/Equity | -0.2 x |
Debt/Assets | 1.5 x |
Financial Leverage | -0.1 x |
ContraFect Cybersecurity Score
ContraFect Online and Social Media Presence
ContraFect's Trends
ContraFect News and Updates
August 25, 2020
ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation
Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caused by antibiotic-resistant Gram-negative bacterial pathogens in Cystic Fibrosis Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caus…
August 14, 2020
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
Exebacase Phase 2 study results published in the Journal of Clinical Investigation
July 20, 2020
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
YONKERS, N.Y., July 20, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatenin…
June 17, 2020
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia
June 15, 2020
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatenin…
May 26, 2020
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
YONKERS, N.Y., May 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that Pfizer Inc. (NYSE: PFE) has entere…
ContraFect Blogs
ContraFect Frequently Asked Questions
When was ContraFect founded?
ContraFect was founded in 2008.
Who are ContraFect key executives?
ContraFect's key executives are Roger J. Pomerantz, David N. Low and Michael J. Otto.
How many employees does ContraFect have?
ContraFect has 24 employees.
Who are ContraFect competitors?
Competitors of ContraFect include Sovicell, Affilogic and Bioz.
Where is ContraFect headquarters?
ContraFect headquarters is located at 28 Wells Ave, Yonkers.
Where are ContraFect offices?
ContraFect has an office in Yonkers.
How many offices does ContraFect have?
ContraFect has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies